← 483 OBSERVATION EXPLORER

FDA 483 OBSERVATION · #278 OF 1,000 MOST-CITED

Equipment for Environmental Control

FDA cited this observation 78 times across 74 firms in recent inspections. Below: how it breaks down by program area and fiscal year, and real examples of how FDA worded it on Form FDA 483.

BY PROGRAM AREA
Drugs78
BY FISCAL YEAR
FY20266
FY20259
FY20247
FY20237
FY20228
FY20216
FY20207
FY201911
FY20189
FY20178

How FDA worded it — real examples

Equipment for adequate control over air pressure is not provided when appropriate for the manufacture, processing, packing or holding of a drug product.

Perrigo New York, Inc. · Bronx, New York · Drugs · 2026-05-08

Equipment for adequate control over air pressure is not provided when appropriate for the manufacture, processing, packing or holding of a drug product.

Element Materials Technology Boston - Acton Inc. · Acton, Massachusetts · Drugs · 2026-05-04

Equipment for adequate control over humidity and temperature is not provided when appropriate for the manufacture, processing, packing or holding of a drug product.

Gallant Pet Inc · San Diego, California · Drugs · 2026-02-27

Equipment for adequate control over humidity and temperature is not provided when appropriate for the manufacture, processing, packing or holding of a drug product.

Tarmac Products, Inc. · Miami Gardens, Florida · Drugs · 2026-02-06

Equipment for adequate control over humidity and temperature is not provided when appropriate for the manufacture, processing, packing or holding of a drug product.

Schmid & Son Packaging Inc · Cottage Grove, Minnesota · Drugs · 2025-12-16

Equipment for adequate control over temperature is not provided when appropriate for the manufacture, processing, packing or holding of a drug product.

EO Products, LLC · San Rafael, California · Drugs · 2025-10-23

Related SPEQ references

Where to read the requirements behind this observation area on SPEQ. These are SPEQ's topic and audience pages — not an FDA classification of the citation.

Pharma industry

Examples are a representative sample of FDA's published inspection observations. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →